Treats Manic and Mixed Episodes associated with Bipolar I Disorder. ANDA 205363, held by Prinston. Aripiprazole.
As of Nov 16, 2026, ANDA 205363 (Aripiprazole), held by Prinston, was first approved by FDA on Dec 4, 2017, with 0 approved supplements and 0 published complete response letters.
Aripiprazole Tablets are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2017 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters